<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0124-0064</journal-id>
<journal-title><![CDATA[Revista de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. salud pública]]></abbrev-journal-title>
<issn>0124-0064</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Salud Publica, Facultad de Medicina - Universidad Nacional de Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0124-00642010000400010</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Prevalência de síndrome metabólica em homens]]></article-title>
<article-title xml:lang="en"><![CDATA[Metabolic syndrome prevalence in males]]></article-title>
<article-title xml:lang="es"><![CDATA[Prevalencia del síndrome metabólico en hombres]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pelegrini]]></surname>
<given-names><![CDATA[Andreia]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santos-Silva]]></surname>
<given-names><![CDATA[Diego A]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Petroski]]></surname>
<given-names><![CDATA[Edio L]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Glaner]]></surname>
<given-names><![CDATA[Maria F]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Federal de Santa Catarina Núcleo de Pesquisa em Cineantropometria e Desempenho Humano ]]></institution>
<addr-line><![CDATA[Florianópolis Santa Catarina]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade Católica de Brasília  ]]></institution>
<addr-line><![CDATA[Brasília ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2010</year>
</pub-date>
<volume>12</volume>
<numero>4</numero>
<fpage>635</fpage>
<lpage>646</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0124-00642010000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0124-00642010000400010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0124-00642010000400010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivos Verificar a prevalência da síndrome metabólica (SM) em funcionários de uma empresa metalúrgica do Distrito Federal, por faixa etária e classificação étnico-racial; comparar indicadores bioquímicos, antropométricos e hemodinÃ¢micos, de acordo com ausência e presença da SM. Métodos Participaram do estudo 125 homens (20-69 anos). As seguintes variáveis foram coletadas: idade, etnia, massa corporal, estatura, índice de massa corporal (IMC), circunferência do abdômen (CA), glicemia, triglicerídeos, colesterol total (CT), lipoproteína de alta densidade (HDL-c) e pressão arterial sistólica (PAS) e diastólica (PAD). Resultados A prevalência de SM foi de 28 %. Os indivíduos com presença da SM apresentaram valores superiores de triglicerídeos, IMC, CA, PAS, PAD e inferiores de HDL-c. Observou-se aumento na presença de SM com o avanço da idade, em maior proporção (45,9 %) naqueles com idade superior a 40 anos. Conclusões A SM foi elevada em homens trabalhadores de uma empresa metalúrgica e esta se associou com a idade.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objective Determining metabolic syndrome (MS) prevalence amongst employees from a steel company in Distrito Federal according to age and ethnic-racial classification, comparing biochemical, anthropometric and hemodynamic indicators according to MS presence or absence. Methods A total of 125 men (aged 20-69) participated in the study. Data was collected regarding age, ethnic origin, body weight, height, body mass index (BMI), waist circumference, glucose, triglycerides, total cholesterol, high-density lipoprotein (HDL-c), systolic (SBP) and diastolic blood pressure (DBP). Results MS prevalence was 28 %. Subjects suffering from MS presented higher triglyceride levels, had greater BMI, waist circumference, SBP and DBP and lower HDL-c. Increased MS frequency was observed with age, having higher frequency (45.9 %) amongst subjects aged more than 40. Conclusions MS prevalence was high amongst steel company workers; the condition was associated with age.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Objetivos Investigar la prevalencia del síndrome metabólico (SM) en los empleados de una empresa metalúrgica en el Distrito Federal, por edad y clasificación etno-racial; comparar los indicadores bioquímicos, antropométricos y hemodinámicos, según la presencia o ausencia de SM. Métodos El estudio incluyó a 125 hombres (20-69 años). Se incluyeron las siguientes variables: edad, etnia, masa corporal, talla (estatura), índice de masa corporal (IMC), circunferencia abdominal (CA), glucosa, triglicéridos, colesterol total (CT), lipoproteínas de alta densidad (HDL-c) y la presión arterial sistólica (PAS) y diastólica (PAD). Resultados La prevalencia del SM fue de 28 %. Los individuos con presencia del síndrome metabólico mostraron valores altos de triglicéridos, IMC, CA, PAS, PAD y bajos valores de HDL-C. Se observó también, un aumento en la presencia del SM con el avanzo de la edad y una mayor proporción (45,9%) en los mayores de 40 años de edad. Conclusiones El SM presentó una alta prevalencia en los trabajadores de una empresa metalúrgica, lo cual se asoció con la edad.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Doenças cardiovasculares]]></kwd>
<kwd lng="pt"><![CDATA[glicemia]]></kwd>
<kwd lng="pt"><![CDATA[hipertensão]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular disease]]></kwd>
<kwd lng="en"><![CDATA[blood glucose]]></kwd>
<kwd lng="en"><![CDATA[high blood pressure]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades cardiovasculares]]></kwd>
<kwd lng="es"><![CDATA[glicemia]]></kwd>
<kwd lng="es"><![CDATA[hipertensión]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <center>       <p><font size="4" face="Verdana"><b>Preval&ecirc;ncia de s&iacute;ndrome metab&oacute;lica      em homens</b></font></p>   </center>     <p align="center"><font size="3" face="Verdana"><b>Metabolic syndrome prevalence in males</b></font></p>     <p align="center"><b><font size="3" face="Verdana">Prevalencia del s&iacute;ndrome metab&oacute;lico en hombres</font></b></p>     <p align="center">&nbsp;</p> <font size="2" face="Verdana">     <p><b>Andreia Pelegrini<sup>1</sup>, Diego A.    Santos-Silva<sup>1,</sup>, Edio L. Petroski<sup>1  </sup> y Maria F. Glaner<sup>2</sup> </b></p>     <p>1 N&uacute;cleo de Pesquisa em Cineantropometria e Desempenho Humano. Universidade Federal de    Santa Catarina. Florian&oacute;polis, Santa Catarina, Brasil. <a href="mailto:a.pelegrini@yahoo.com.br">a.pelegrini@yahoo.com.br</a>,    <a href="mailto:diegoaugustoss@yahoo.com.br">diegoaugustoss@yahoo.com.br</a>, <a href="mailto:petroski@cds.ufsc.br">petroski@cds.ufsc.br</a>    <br>2 Universidade Cat&oacute;lica de Bras&iacute;lia. Bras&iacute;lia, Brasil. <a href="mailto:mfglaner@gmail.br">mfglaner@gmail.br</a></p>     <p>Recebido 28 Janeiros 2010/Enviado para Modifica&ccedil;&atilde;o 25 Setembro 2010/Aprovado 9 Novembro 2010 </p> </font> <hr size="1" /> <font size="2" face="Verdana"></font>     <p><font size="3" face="Verdana"><b>RESUMO</b></font></p> <font size="2" face="Verdana">     ]]></body>
<body><![CDATA[<p><b>Objetivos </b>Verificar a preval&ecirc;ncia da s&iacute;ndrome metab&oacute;lica (SM) em funcion&aacute;rios    de uma empresa metal&uacute;rgica do Distrito Federal, por faixa et&aacute;ria e classifica&ccedil;&atilde;o  &eacute;tnico-racial; comparar indicadores bioqu&iacute;micos, antropom&eacute;tricos e hemodin&acirc;micos,    de acordo com aus&ecirc;ncia e presen&ccedil;a da SM.    <br>   <b>M&eacute;todos </b>Participaram do estudo 125 homens (20-69 anos). As seguintes    vari&aacute;veis foram coletadas: idade, etnia, massa corporal, estatura, &iacute;ndice de massa    corporal (IMC), circunfer&ecirc;ncia do abd&ocirc;men (CA), glicemia, triglicer&iacute;deos, colesterol total    (CT), lipoprote&iacute;na de alta densidade (HDL-c) e press&atilde;o arterial sist&oacute;lica (PAS) e    diast&oacute;lica (PAD).       <br> <b>Resultados </b>A preval&ecirc;ncia de SM foi de 28 %. Os indiv&iacute;duos com presen&ccedil;a da    SM apresentaram valores superiores de triglicer&iacute;deos, IMC, CA, PAS, PAD e    inferiores de HDL-c. Observou-se aumento na presen&ccedil;a de SM com o avan&ccedil;o da idade,    em maior propor&ccedil;&atilde;o (45,9 %) naqueles com idade superior a 40 anos.       <br><b>Conclus&otilde;es </b>A SM foi elevada em homens trabalhadores de uma    empresa metal&uacute;rgica e esta se associou com a idade.  </p>     <p><b>Palavras-chave</b>: Doen&ccedil;as cardiovasculares, glicemia, hipertens&atilde;o    (<i>fonte: DeCS, BIREME</i>). </p> </font> <hr size="1" /> <font size="2" face="Verdana"> </font>     <p><font size="3" face="Verdana"><b>ABSTRACT</b></font></p> <font size="2" face="Verdana">     <p><b>Objective </b>Determining metabolic syndrome (MS) prevalence amongst        employees from a steel company in Distrito Federal according to age and        ethnic-racial classification, comparing biochemical, anthropometric and hemodynamic        indicators according to MS presence or absence.       <br><b>Methods </b>A total of 125 men (aged 20-69) participated in the study. Data was        collected regarding age, ethnic origin, body weight, height, body mass index (BMI),        waist circumference, glucose, triglycerides, total cholesterol, high-density lipoprotein        (HDL-c), systolic (SBP) and diastolic blood pressure (DBP).        <br><b>Results </b>MS prevalence was 28 %. Subjects suffering from MS presented        higher triglyceride levels, had greater BMI, waist circumference, SBP and DBP and        lower HDL-c. Increased MS frequency was observed with age, having higher        frequency (45.9 %) amongst subjects aged more than 40.    <br>   <b>Conclusions</b> MS prevalence was high amongst steel company workers; the        condition was associated with age.</p>     ]]></body>
<body><![CDATA[<p><b>Key Words</b>: Cardiovascular disease, blood glucose, high blood pressure  (<i>source: MeSH, NLM</i>) </p> </font> <hr size="1" /> <font size="2" face="Verdana"> </font>     <p><font size="3" face="Verdana"><b>RESUMEN</b></font></p> <font size="2" face="Verdana">     <p><b>Objetivos </b>Investigar la prevalencia del s&iacute;ndrome metab&oacute;lico (SM) en los      empleados de una empresa metal&uacute;rgica en el Distrito Federal, por edad y clasificaci&oacute;n      etno-racial; comparar los indicadores bioqu&iacute;micos, antropom&eacute;tricos y      hemodin&aacute;micos, seg&uacute;n la presencia o ausencia de SM.    <br> <b>M&eacute;todos </b>El estudio incluy&oacute; a 125 hombres (20-69 a&ntilde;os). Se incluyeron las      siguientes variables: edad, etnia, masa corporal, talla (estatura), &iacute;ndice de masa corporal      (IMC), circunferencia abdominal (CA), glucosa, triglic&eacute;ridos, colesterol total      (CT), lipoprote&iacute;nas de alta densidad (HDL-c) y la presi&oacute;n arterial sist&oacute;lica (PAS) y      diast&oacute;lica (PAD).     <br><b>Resultados </b>La prevalencia del SM fue de 28 %. Los individuos con presencia      del s&iacute;ndrome metab&oacute;lico mostraron valores altos de triglic&eacute;ridos, IMC, CA,  PAS, PAD      y bajos valores de HDL-C. Se observ&oacute; tambi&eacute;n, un aumento en la presencia del      SM con el avanzo de la edad y una mayor proporci&oacute;n (45,9%) en los mayores de      40 a&ntilde;os de edad.     <br><b>Conclusiones </b>El SM present&oacute; una alta prevalencia en los trabajadores de  una empresa metal&uacute;rgica, lo cual  se asoci&oacute; con la edad. </p>     <p><b>Palabras Clave:</b> Enfermedades cardiovasculares, glicemia, hipertensi&oacute;n  (<i>fuente; DeCS, BIREME</i>).</p> </font> <hr size="1" /> <font size="2" face="Verdana">     <p>As mudan&ccedil;as ocorridas nos padr&otilde;es econ&ocirc;micos e culturais, nas &uacute;ltimas    d&eacute;cadas, t&ecirc;m alterado de forma significativa o modo de vida das pessoas.    Alguns fatores podem estar contribuindo para o aumento da preval&ecirc;ncia de doen&ccedil;as cr&ocirc;nicas n&atilde;o-transmiss&iacute;veis (doen&ccedil;as cardiovasculares,    diversos tipos de c&acirc;ncer, diabetes e obesidade), entre os quais destacam-se:    h&aacute;bitos alimentares (alimenta&ccedil;&atilde;o fora de casa crescimento na oferta de    refei&ccedil;&otilde;es r&aacute;pidas), estilo de vida (meios de deslocamento, equipamentos eletr&ocirc;nicos)  e estresse (1,2). </p>     <p>As doen&ccedil;as cardiovasculares representam a primeira causa de    morte nos pa&iacute;ses desenvolvidos e, tamb&eacute;m, vem crescendo muito nos pa&iacute;ses    em desenvolvimento (3). Dados do Brasil mostram que, aproximadamente,    dois milh&otilde;es de pessoas foram acometidas por eventos cardiovasculares, no    ano de 2004, cujos custos chegaram a 30,8 bilh&otilde;es (4). </p>     <p>A s&iacute;ndrome metab&oacute;lica (SM) consiste em um conjunto de fatores de    risco cardiovasculares, identificados por meio da hipertens&atilde;o arterial,    obesidade abdominal, aumento dos triglicer&iacute;deos, diminui&ccedil;&atilde;o das lipoprote&iacute;nas de    alta densidade (HDL-c) e intoler&acirc;ncia &agrave; glicose/diabetes tipo 2, os quais    s&atilde;o encontrados, freq&uuml;entemente, em pessoas com patologias    cardiovasculares (5). Neste sentido, h&aacute; um grande interesse em se estudar os fatores de    risco para as doen&ccedil;as cardiovasculares, e conseq&uuml;entemente, a SM, que    representa, na atualidade, a anormalidade metab&oacute;lica mais comum em cardiopatas (6).    </p>     ]]></body>
<body><![CDATA[<p>A preval&ecirc;ncia da SM ainda &eacute; pouco conhecida em amostras    brasileiras. Pesquisas conduzidas em adultos das cidades de Vit&oacute;ria  ES (7) e    Virgem das Gra&ccedil;as  MG (8), revelaram preval&ecirc;ncia de SM de 29,8 %    (homens: 29,3 %; mulheres: 30,1 %) e 21,6 % (homens: 7,7 %; mulheres: 33,6    %), respectivamente. Em estudos internacionais, foram verificadas    preval&ecirc;ncias de 12,4 % a 28,5 % nos homens e de 10,7 % a 40,5 % nas mulheres (9-12). </p>     <p>Devido ao aumento das taxas de sobrepeso/obesidade, com    subsequente eleva&ccedil;&atilde;o dos fatores de risco para as doen&ccedil;as cardiovasculares,    faz-se necess&aacute;rio realizar estudos com o prop&oacute;sito de verificar a presen&ccedil;a de    SM em adultos. Neste sentido, os objetivos do presente estudo foram: a)    verificar a preval&ecirc;ncia da SM em funcion&aacute;rios de uma empresa metal&uacute;rgica do    Distrito Federal, por faixa et&aacute;ria e classifica&ccedil;&atilde;o  &eacute;tnico-racial; b) comparar os indicadores bioqu&iacute;micos, antropom&eacute;tricos e hemodin&acirc;micos, de acordo    com aus&ecirc;ncia e presen&ccedil;a da SM. </p> </font>     <p align="center"><font size="3" face="Verdana"><b>M&Eacute;TODOS</b></font></p>     <center>   <font size="2" face="Verdana">   </font> </center> <font size="2" face="Verdana">     <p>Popula&ccedil;&atilde;o e amostra </p>     <p>Esse estudo, com delineamento transversal, foi conduzido em    homens, funcion&aacute;rios de uma ind&uacute;stria metal&uacute;rgica do Distrito Federal.    Inicialmente, o estudo foi composto por  200 funcion&aacute;rios que atuavam na    administra&ccedil;&atilde;o, manufatura, transporte e venda de metal.  </p>     <p>Os crit&eacute;rios de exclus&atilde;o aplicados foram: n&atilde;o respeitar o jejum    alimentar de 12 horas; uso de repositores hormonais orais ou injet&aacute;veis,    rem&eacute;dios antilip&ecirc;micos e para o controle do diabetes; uso de cigarros e bebidas    alco&oacute;licas de forma regular  mais do que dois dias na semana; mal-estar agudo    como vertigens ou febre, ou cr&ocirc;nico, como esclerose das veias dos bra&ccedil;os.    Os funcion&aacute;rios foram classificados em tr&ecirc;s categorias de idade: 20-29  anos (32,8 %), 30-39 anos (37,6 %) e &gt; 40 anos (29,6 %).</p>     <p> Procedimentos para coleta   </p>     <p>Inicialmente, foi contatado o departamento de Recursos Humanos    da empresa, cujos objetivos e procedimentos da pesquisa foram expostos.    Ap&oacute;s a autoriza&ccedil;&atilde;o, durante a aula de gin&aacute;stica laboral, os funcion&aacute;rios    foram convidados a participar do estudo e receberam informa&ccedil;&otilde;es pr&eacute;vias sobre    o prop&oacute;sito e a necessidade de seguir jejum alimentar de pelo menos 12h    para realizar o exame de sangue. </p>     <p>Os funcion&aacute;rios, que concordaram em participar, assinaram um termo    de consentimento livre e esclarecido que detalhava todos os procedimentos    que seriam realizados para a coleta de dados, garantindo o total anonimato    das informa&ccedil;&otilde;es. Esta pesquisa foi aprovada pelo Comit&ecirc; de &Eacute;tica e Pesquisa    da Universidade Cat&oacute;lica de Bras&iacute;lia (Parecer    n<sup>o</sup> 04/2005). </p>     ]]></body>
<body><![CDATA[<p>Vari&aacute;veis do estudo   A classifica&ccedil;&atilde;o &eacute;tnico-racial de cada indiv&iacute;duo foi feita por um &uacute;nico    avaliador, devidamente treinado. No caso de d&uacute;vida, o avaliador perguntava ao    sujeito a qual etnia ele pertencia. Os indiv&iacute;duos foram divididos em tr&ecirc;s    grupos: brancos, mulatos e pretos. </p>     <p>A massa corporal (MC) e a estatura (ES) foram mensuradas seguindo    os procedimentos descritos por Alvarez &amp; Pavan (13). Para isto, foi usada    uma balan&ccedil;a Filizola (escala de 0,1 kg) e estadi&ocirc;metro acoplado (escala de    0,5 cm). A partir das medidas de MC e ES, calculou-se o &iacute;ndice de massa    corporal (IMC=MC<sub>kg</sub>/ES<sub>m</sub><sup>2</sup>). A medida da circunfer&ecirc;ncia do abdomen (CA) foi    obtida com uma fita m&eacute;trica, sendo a fita posicionada na menor curvatura    localizada entre o &uacute;ltimo arco costal e a crista il&iacute;aca. </p>     <p>A press&atilde;o arterial (PA) foi medida em um &uacute;nico momento, no    bra&ccedil;o esquerdo, com esfigmoman&ocirc;metro    Premium<sup>&reg; </sup>. Antes da medida, cada    sujeito ficou deitado por 20 min, sendo a medida realizada nesta posi&ccedil;&atilde;o.    A temperatura da sala foi mantida entre 20 e    22&deg;C.  </p>     <p>A coleta sangu&iacute;nea foi realizada, na enfermaria da metal&uacute;rgica, por    um profissional habilitado legalmente para o procedimento. Para tanto,    os volunt&aacute;rios permaneceram sentados, com o bra&ccedil;o apoiado sobre um    suporte. Em seguida, tiveram seu bra&ccedil;o garroteado, aproximadamente, no ponto    m&eacute;dio do &uacute;mero e ent&atilde;o, realizou-se a anti-sepsia do local da coleta com    algod&atilde;o embebido em &aacute;lcool.  </p>     <p>Com a ajuda de um adaptador de agulhas para coletas m&uacute;ltiplas,    foi introduzida uma agulha descart&aacute;vel de 25x8 mm em uma das veias da    fossa antecubital do bra&ccedil;o. Aproximadamente, 3 mL de sangue foram    coletados em cada tubo a v&aacute;cuo (<i>Bencton    Dickinson</i>), um com EDTA e outro com fluoreto. Os tubos com o sangue foram colocados em uma caixa    t&eacute;rmica com gelo, para depois serem levados ao laborat&oacute;rio. O tempo entre a    coleta e a centrifuga&ccedil;&atilde;o n&atilde;o excedeu &agrave; 2h.  </p>     <p>Nas an&aacute;lises bioqu&iacute;micas, foram utilizados um espectrofot&ocirc;metro    semi-autom&aacute;tico da <i>Bioplus</i>, modelo BIO-2000 e reagentes bioqu&iacute;micos da    marca Doles. Todos os procedimentos descritos pelos fabricantes    do espectrofot&ocirc;metro e dos reagentes foram seguidos.  </p>     <p>Foram quantificados os n&iacute;veis de glicemia, triglicer&iacute;deos e HDL-c. A    SM foi identificada, levando-se em    considera&ccedil;&atilde;o os par&acirc;metros definidos    pela Primeira Diretriz Brasileira de Diagn&oacute;stico e Tratamento da    S&iacute;ndrome Metab&oacute;lica (6), a qual est&aacute; baseada nos crit&eacute;rios definidos pelo    National Cholesterol Education Program&#39;sAdult Treatment Panel III    (NCEP-ATP III). Segundo o NCEP-ATP III, a SM representa a combina&ccedil;&atilde;o de,    pelo menos, tr&ecirc;s dos cinco par&acirc;metros usados para caracteriz&aacute;-la: CA    elevada (&gt;102 cm), aumento de triglicer&iacute;deos    (<u>&gt;</u>150 mg/dL), HDL-c reduzido (&lt;40 mg/dL), glicemia elevada    (<u>&gt;</u>110 mg/dL) e aumento da press&atilde;o arterial    sist&oacute;lica (PAS <u>&gt;</u>130 mmHg) e/ou press&atilde;o arterial diast&oacute;lica (PAD  <u>&gt;</u>85 mmHg).  </p>     <p>An&aacute;lise estat&iacute;stica   Para todas as an&aacute;lises, foi usado o <i>Statistical Package for the    Social Sciences</i>-vers&atilde;o 15.0. A normalidade dos dados foi realizada por meio    do teste de <i>Kolmogorov Smirnov.</i> As m&eacute;dias foram comparadas,    utilizando-se o teste <i>&quot;t&quot;</i> de    <i>Student</i> para amostras independentes (dados param&eacute;tricos)    e U de Mann-Whitney (dados n&atilde;o-param&eacute;tricos). Para verificar as    poss&iacute;veis associa&ccedil;&otilde;es entre a ocorr&ecirc;ncia da SM e as caracter&iacute;sticas &eacute;tnico-raciais    e idade, foi utilizado o teste qui-quadrado. O n&iacute;vel de signific&acirc;ncia para    todos os testes foi estabelecido em 5 %.  </p> </font>     <p align="center"><font size="3" face="Verdana"><b>RESULTADOS</b></font></p>     <center>   <font size="2" face="Verdana">   </font> </center> <font size="2" face="Verdana">     ]]></body>
<body><![CDATA[<p>Participaram do estudo 125 funcion&aacute;rios da ind&uacute;stria metal&uacute;rgica, com    idade de 20 a 69 anos, representando 62,5 % dos trabalhadores da empresa.    As m&eacute;dias de MC, ES e IMC observadas nos indiv&iacute;duos foram 72,51    (&plusmn; 10,88), 168,20 (&plusmn; 6,96) e 25,65 (&plusmn; 3,45), respectivamente. A maioria dos    funcion&aacute;rios &eacute; advinda da regi&atilde;o Nordeste (48,3 %), seguida da Centro-Oeste (35,3    %); 15,3 % da regi&atilde;o Sudeste e 1,1 % da regi&atilde;o Sul do    Brasil. </p>     <p>A <a href="#(fig1)">Figura 1</a> mostra a contribui&ccedil;&atilde;o relativa dos cinco par&acirc;metros para    o diagn&oacute;stico da SM na amostra estudada. Os tr&ecirc;s par&acirc;metros mais    frequentes foram: baixo HDL-c (52,8 %; IC95 %: 44,1-61,3), elevados triglicer&iacute;deos (50    %; IC95 %: 41,4-58,6) e hipertens&atilde;o arterial (48,8 %; IC95 %: 40,2-57,5),    seguidos da presen&ccedil;a de obesidade abdominal (4,8 %; IC95 %: 2,2-10,1) e aumento    da glicemia (1,6 %; IC95 %: 0,4-5,6).     <p align="center"><a name="(fig1)"><img src="img/revistas/rsap/v12n4/v12n4a10fig1.gif"></a>  </p>     <p>Os indicadores bioqu&iacute;micos, antropom&eacute;tricos e hemodin&acirc;micos    dos indiv&iacute;duos com presen&ccedil;a e aus&ecirc;ncia da SM, s&atilde;o apresentados na <a href="#(tab1)">Tabela 1</a>. Os indiv&iacute;duos com presen&ccedil;a da SM apresentaram valores superiores    de triglicer&iacute;deos, glicemia, IMC, CA, PAS, PAD e inferiores de HDL-c.     <p align="center"><a name="(tab1)"><img src="img/revistas/rsap/v12n4/v12n4a10tab1.gif"></a>  </p>     <p>A <a href="#(tab2)">Tabela 2</a> apresenta a preval&ecirc;ncia de SM por faixa et&aacute;ria e    classifica&ccedil;&atilde;o &eacute;tnico-racial. A preval&ecirc;ncia de SM encontrada nos trabalhadores    metal&uacute;rgicos foi de 28 %. Os resultados do qui-quadrado indicam associa&ccedil;&atilde;o entre a    SM e faixa et&aacute;ria. Percebe-se um incremento da propor&ccedil;&atilde;o de indiv&iacute;duos    com presen&ccedil;a de SM, conforme o avan&ccedil;o da idade, com maior preval&ecirc;ncia    nos indiv&iacute;duos com idade superior a 40 anos (45,9 %). N&atilde;o foi    verificada associa&ccedil;&atilde;o entre SM e classifica&ccedil;&atilde;o &eacute;tnico-racial.        <p align="center"><a name="(tab2)"><img src="img/revistas/rsap/v12n4/v12n4a10tab2.gif"></a>  </p> </font>     <p align="center"> <font size="3" face="Verdana"><b>DISCUSS&Atilde;O</b></font> </p>     <center>   <font size="2" face="Verdana">   </font> </center> <font size="2" face="Verdana">     <p>A preval&ecirc;ncia de SM observada nos indiv&iacute;duos do presente estudo foi de 28    %. Preval&ecirc;ncias menores de SM foram encontradas em pesquisas realizadas    na Gr&eacute;cia (24,8 %) (14), Estados Unidos (22,8 %) (15), Ar&aacute;bia Saudita (21 %)    (16) e Cor&eacute;ia do Sul (14,2 %) (17). No Brasil, estudos realizados em adultos    revelaram preval&ecirc;ncia superior (29,8 %) (7) e inferior (21,6 %) (8), quando comparado    aos resultados encontrados no presente estudo. </p>     ]]></body>
<body><![CDATA[<p>Quando os fatores de risco para as doen&ccedil;as cardiovasculares    foram analisados isoladamente, observou-se que os mais frequentes foram,    nesta ordem crescente, o HDL-c,    triglicer&iacute;deos, hipertens&atilde;o arterial,    obesidade abdominal e glicemia. Em estudo conduzido em adultos (25-64 anos),    de ambos os sexos, de Vit&oacute;ria - ES, o par&acirc;metro da SM mais frequente foi    a hipertens&atilde;o arterial, seguido de hipertrigliceridemia, baixo    HDL-c, hiperglicemia e obesidade abdominal (7). Isto evidencia que de uma    regi&atilde;o para a outra os fatores de risco s&atilde;o distribu&iacute;dos de maneiras diferentes    na popula&ccedil;&atilde;o. Consequentemente, as a&ccedil;&otilde;es direcionadas ao monitoramento e  &agrave; preven&ccedil;&atilde;o destes fatores de risco devem considerar as    diferen&ccedil;as demogr&aacute;ficas, s&oacute;cio-econ&ocirc;micas e de estilo de vida (18,19). Assim, as    doen&ccedil;as cardiovasculares podem ser modificadas drasticamente nas pr&oacute;ximas    cinco d&eacute;cadas (18).  </p>     <p>Em rela&ccedil;&atilde;o ao HDL-c, 52,8 % dos sujeitos apresentaram valores    baixos. Na Ar&aacute;bia Saudita, observou-se que 77,2 % dos indiv&iacute;duos estavam    nesta situa&ccedil;&atilde;o (16). Preval&ecirc;ncia inferior a encontrada no presente estudo foi    verificada na Turquia (21,1 %) (20), Jap&atilde;o (9,2 %) (21), Cor&eacute;ia do Sul (24,5 %) (17)    e &Aacute;frica Ocidental (13,0 %) (22). Estudo realizado em amostra rural do Vale    do Jequitinhonha, Minas Gerais, Brasil, revelou que 37,1 % dos sujeitos    apresentaram n&iacute;veis baixos de HDL-c (8). O baixo n&iacute;vel de HDL-c &eacute; um fator de    risco preditivo para a doen&ccedil;a arterial coronariana, estimando-se que o aumento de    1 mg/dL de HDL-c reduz em 4 % o risco de doen&ccedil;as cardiovasculares    (23,24).  </p>     <p>Foi observado que 50 % dos sujeitos investigados, na presente    casu&iacute;stica, apresentaram n&iacute;veis elevados de triglicer&iacute;deos. Preval&ecirc;ncias inferiores    foram observadas na Turquia (12,7 %) (20) e na Cor&eacute;ia do Sul (35,0 %) (17).    Os dados obtidos no presente estudo revelam uma situa&ccedil;&atilde;o de alerta, pois    a hipertrigliceridemia &eacute; um fator de risco independente para o    desenvolvimento das doen&ccedil;as coronarianas (25). </p>     <p>Em rela&ccedil;&atilde;o a hipertens&atilde;o arterial, verificou-se preval&ecirc;ncia de 48,8    %. Resultados semelhantes foram observados no Jap&atilde;o (46,6 %)    (21). Preval&ecirc;ncias superiores foram encontradas na Gr&eacute;cia (71 %) (14) e no    Brasil (65,8 %) (8), e inferiores na Ar&aacute;bia Saudita (27,9 %) (16), &Aacute;frica    Ocidental (23 %) (22) e Cor&eacute;ia do Sul (44,7 %) (17). Em pesquisa realizada    com adultos acompanhados por uma unidade de sa&uacute;de da fam&iacute;lia de Jequi&eacute;    Bahia, observou-se que a freq&uuml;&ecirc;ncia de hipertens&atilde;o arterial foi de 28,7    % (26).   A hipertens&atilde;o arterial representa um dos agravos    cr&ocirc;nicos mais comuns e com repercuss&otilde;es cl&iacute;nicas acentuadas, sendo considerada um fator    de risco independente, linear e cont&iacute;nuo para as doen&ccedil;as cardiovasculares.    Neste sentido, apresenta altos custos, decorrentes, principalmente, das    suas complica&ccedil;&otilde;es, tais como: doen&ccedil;a cerebrovascular, doen&ccedil;a arterial    coronariana, insufici&ecirc;ncia card&iacute;aca, insufici&ecirc;ncia renal cr&ocirc;nica e doen&ccedil;a vascular    perif&eacute;rica (27,28). </p>     <p>Quanto &agrave; glicemia elevada, 4,7 % dos sujeitos apresentaram    valores elevados. Embora a preval&ecirc;ncia reportada no presente estudo seja    inferior &agrave;s verificadas por outros estudos feitos no Brasil (8) e do exterior (14),    aten&ccedil;&atilde;o deve ser dada a estes sujeitos, pois n&iacute;veis elevados de glicemia    sangu&iacute;nea, al&eacute;m de representar risco cardiovascular, est&atilde;o associados diretamente    ao desenvolvimento de Diabetes mellitus tipo 2 (29).  </p>     <p>Os resultados demonstraram que 4,8 % dos sujeitos    apresentaram obesidade abdominal. Resultado semelhante foi verificado em estudo    realizado em uma amostra rural de JequitinhonhaMinas Gerais (4,3 %) (8).    Em contrapartida, na Cor&eacute;ia do Sul (1,3 %) (17) preval&ecirc;ncias inferiores    foram verificadas. J&aacute; na Gr&eacute;cia (82 %) (14) e &Aacute;frica Ocidental (32 %)    (22), preval&ecirc;ncias mais elevadas foram verificadas. Algumas suposi&ccedil;&otilde;es para    as diferen&ccedil;as encontradas entre os estudos devem ser abordadas: a.    Diferen&ccedil;a nas idades dos sujeitos; b. Alimenta&ccedil;&atilde;o t&iacute;pica de cada pa&iacute;s; c. N&iacute;vel    de atividade f&iacute;sica; d) utiliza&ccedil;&atilde;o de pontos de corte diferentes entre os estudos. </p>     <p>Os indiv&iacute;duos com presen&ccedil;a de SM apresentaram maiores valores    m&eacute;dios de triglicer&iacute;deos, glicemia, IMC, CC, PAS e PAD e menores de    HDL-c. Esses resultados corroboram, em parte, o estudo (7) realizado em Vit&oacute;ria    - ES, no qual foi observado que os indiv&iacute;duos com SM apresentaram    maiores n&iacute;veis de triglicer&iacute;deos, glicemia, IMC, PAS e PAD, bem como    menores n&iacute;veis de HDL-c.  </p>     <p>&Eacute; bem documentado que a idade contribui para o aparecimento da    SM (8,14,21,30). No presente estudo, foi verificada associa&ccedil;&atilde;o entre SM e    faixa et&aacute;ria, na qual observou-se aumento na frequ&ecirc;ncia da SM conforme o    avan&ccedil;o da idade. Esses resultados corroboram as pesquisas internacionais    (14,17,20) e nacional (8). Curiosamente, o estudo realizado em Vit&oacute;ria-ES, Brasil,    revelou maior preval&ecirc;ncia de SM nos extratos et&aacute;rios mais jovens (7). </p>     <p>N&atilde;o foi verificado associa&ccedil;&atilde;o entre SM e classifica&ccedil;&atilde;o  &eacute;tnico-racial. Dados do estudo    <i>NHANES-III</i>, feito na popula&ccedil;&atilde;o da Am&eacute;rica do Norte,                      mostraram maior preval&ecirc;ncia de s&iacute;ndrome metab&oacute;lica entre americanos de                      origem mexicana e negros, quando comparados com brancos (31). </p>     <p>As principais limita&ccedil;&otilde;es do presente estudo s&atilde;o: 1. O uso de um    <i>kit </i>comercial, n&atilde;o comumente adotado como &quot;padr&atilde;o ouro&quot; no m&eacute;todo    de espectrofotometria enzim&aacute;tica e, o espectrofot&ocirc;metro usado ser    semi-autom&aacute;tico, o que pode aumentar as chances de erro. O fato de ter    sido usado este <i>kit </i>pode diminuir a validade dos resultados. No entanto, ele &eacute;    o mais usado no Centro-Oeste do Brasil, o que justifica o seu uso neste    estudo, uma vez que a amostra reside nesta regi&atilde;o. Al&eacute;m do que a sensibilidade    do <i>kit </i>usado &eacute; de 1 mg/dL, com coeficiente de varia&ccedil;&atilde;o para a    reprodutibilidade, oscilando de 1,26 % a 2,76 %, e de 0,79 % a 1,04 % para a repetitividade;    2. A amostra reduzida de sujeitos, o que impede a generaliza&ccedil;&atilde;o e a    extrapola&ccedil;&atilde;o dos resultados; 3. O delineamento transversal do estudo,    impossibilitando verificar a rela&ccedil;&atilde;o de causalidade, apenas de associa&ccedil;&atilde;o entre as    vari&aacute;veis. No entanto, cabe destacar que estudos com esse delineamento s&atilde;o    relevantes para a identifica&ccedil;&atilde;o de problemas, facilitando o desenvolvimento e    execu&ccedil;&atilde;o de estrat&eacute;gias para monitor&aacute;-los e amenizar seus efeitos delet&eacute;rios.    Os resultados obtidos tamb&eacute;m subsidiam a elabora&ccedil;&atilde;o de hip&oacute;teses para    os poss&iacute;veis estudos longitudinais. </p> </font>    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">A partir dos resultados encontrados no presente estudo, conclui-se que    a preval&ecirc;ncia de SM &eacute; elevada em funcion&aacute;rios de uma empresa    metal&uacute;rgica do Distrito Federal. Os indiv&iacute;duos com presen&ccedil;a da SM apresentaram    valores superiores de triglicer&iacute;deos, IMC, CA, PAS, PAD e inferiores de    HDL-c. Observou-se aumento na presen&ccedil;a de SM com o avan&ccedil;o da idade,    com maior propor&ccedil;&atilde;o naqueles com idade superior a 40 anos. Neste sentido,    faz-se necess&aacute;ria interven&ccedil;&atilde;o direcionada para a melhoria da qualidade de    vida, no que tange a ado&ccedil;&atilde;o de um estilo de vida saud&aacute;vel, com fins de reverter    o quadro reportado</font></p>     <p><font size="2" face="Verdana"><b><i>Declara&ccedil;&atilde;o de conflito de    interesses</i></b>: Os autores declaram n&atilde;o haver conflito      de interesses. </font></p>     <p align="center"><b><font size="3" face="Verdana">REFER&Ecirc;NCIAS </font></b></p> <font size="2" face="Verdana">     <!-- ref --><p>1. Pozzan R, Pozzan R, Magalh&atilde;es MEC, Brand&atilde;o AA, Brand&atilde;o AP. Dislipidemia, s&iacute;ndrome metab&oacute;lica    e risco cardiovascular. RSOCERJ 2004; 17(2): 97-104.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000076&pid=S0124-0064201000040001000001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>2. Mendon&ccedil;a CP, Anjos LA. Aspectos das pr&aacute;ticas alimentares e da atividade f&iacute;sica como    determinantes do crescimento do sobrepeso/obesidade no Brasil. Cad Sa&uacute;de P&uacute;blica    2004; 20(3): 698-709.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000077&pid=S0124-0064201000040001000002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  3. Lakka HM, Laaksonen DE, Lakka TA, Niskanem LK, Kumpusalo E, Tuomilehto J et al. The    metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.    JAMA 2002; 288(21): 2709-2716.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000078&pid=S0124-0064201000040001000003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  4. Azambuja MIR, Foppa M, Maranhao MFC, Achutti AC. Impacto econ&ocirc;mico dos casos de doen&ccedil;a    cardiovascular grave no Brasil: uma estimativa baseada em dados secund&aacute;rios. Arq    Bras Cardiol 2008; 91(3): 163-171.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000079&pid=S0124-0064201000040001000004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  5. Brand&atilde;o AP, Nogueira AR, Oliveira JE, Guimar&atilde;es JI, Suplicy H, Brand&atilde;o AA. (Coord). I Diretriz    Brasileira de Diagn&oacute;stico e Tratamento da S&iacute;ndrome Metab&oacute;lica. Arq Bras Cardiol 2005;    84(Supl I): 1-28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000080&pid=S0124-0064201000040001000005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  6. Sociedade Brasileira de Hipertens&atilde;o. I Diretriz Brasileira de Diagn&oacute;stico e Tratamento da    S&iacute;ndrome Metab&oacute;lica. Hipertens&atilde;o 2004; 7(4).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000081&pid=S0124-0064201000040001000006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  7. Salaroli LB, Barbosa GC, Mill JG, Molina MCB. Prevalência de Síndrome Metabólica em Estudo de Base Populacional, Vitória, ES - Brasil. Arq Bras Endocrinol Metab 2007; 51/7: 1143- 1152.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000082&pid=S0124-0064201000040001000007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  8. Vel&aacute;squez-Mel&eacute;ndez G, Gazzinelli A, C&ocirc;rrea-Oliveira R, Pimenta AM, Kac G. Prevalence of    metabolic syndrome in a rural area of Brazil. Sao Paulo Med J 2007; 125(3): 155-162.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000083&pid=S0124-0064201000040001000008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  9. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two    proposed definitions. Diabetes Care 2003; 26(3): 575-581.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000084&pid=S0124-0064201000040001000009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  10. Gang H, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K for the DECODE Study    Group. Prevalence of the metabolic syndrome and its relation to all-cause and    cardiovascular mortality in nondiabetic European men in women. Arch Intern Med 2004;    164(10): 1066-1076.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000085&pid=S0124-0064201000040001000010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  11. Aguilar-Salinas CA, Rojas R, G&oacute;mez-Perez FJ, Valles V, Rios-Torres JM, Franco A. et al. High    prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35(1): 76-81.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000086&pid=S0124-0064201000040001000011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  12. Oh J-Y, Hong YS, Sung Y-A, Connor-Barrett E. Prevalence and factor analysis of metabolic    syndrome in an urban Korean population. Diabetes Care 2004; 27(8): 2027-2032.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000087&pid=S0124-0064201000040001000012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  13. Alvarez BR, Pavan AL. Alturas e comprimentos. En: Petroski EL (Organizador). Antropometria:    t&eacute;cnicas e padroniza&ccedil;&otilde;es. 2. ed. Porto Alegre: EL Petroski; 2003. p. 59-71.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000088&pid=S0124-0064201000040001000013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><br> </p>     <!-- ref --><p>14. Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, Goudevenos IA, Papageorgiou AA, et al.    Awareness, treatment and control of the metabolic syndrome and its components: a    multicentre Greek study. Hellenic J Cardiol 2005; 46(6): 380-386.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000090&pid=S0124-0064201000040001000014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><br> </p>     <!-- ref --><p>15. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic   syndrome: prevalence and associated risk factor findings in the US population from the   Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163 (4): 427-436.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000092&pid=S0124-0064201000040001000015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  16. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome   among Omani adults. Diabetes Care 2003; 26(6): 1781-1785.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000093&pid=S0124-0064201000040001000016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  17. Park HS, Oh SW, Cho S, Choi WH, Kim YS. The metabolic syndrome and associated lifestyle    factors among South Korean adults. Int J Epidemiol 2004; 33(2): 328-336.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000094&pid=S0124-0064201000040001000017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>    <!-- ref --><br>   18. Polanczyk CA. Fatores de risco cardiovascular no Brasil: os pr&oacute;ximos 50 anos. Arq Bras    Cardiol 2005; 84(3): 199-201.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000096&pid=S0124-0064201000040001000018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  19. Vedana EHB, Peres MA, Neves J, Rocha GC, Longo GZ. Preval&ecirc;ncia de obesidade e fatores    potencialmente causais em adultos em regi&atilde;o do sul do Brasil. Arq Bras Endocrinol   Metab 2008; 52(7): 1156-62.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000097&pid=S0124-0064201000040001000019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p>    <!-- ref --><br>   20. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and   associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008;   34(1-3): 36-51.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000099&pid=S0124-0064201000040001000020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  21. Morimoto A, Nishimura R, Suzuki N, Matsudaira T, Taki K, Tsujino D, et al. Low prevalence of   metabolic syndrome and its components in rural Japan. Tohoku J Exp Med 2008; 216(1):   69-75.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000100&pid=S0124-0064201000040001000021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>22. Sodjinou R, Agueh V, Fayomi B, Delisle H. Obesity and cardio-metabolic risk factors in urban   adults of Benin: relationship with socio-economic status, urbanisation, and lifestyle patterns. BMC Public Health 2008;8: 84.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000101&pid=S0124-0064201000040001000022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  23. Mora S, Cook N, Buring J. Physical activity and reduced risk of cardiovascular events:   potential mediating mechanisms. Circulation 2007; 116(19): 2110-2118.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000102&pid=S0124-0064201000040001000023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  24. Zmuda J, Yurgalevich S, Flynn M, et al. Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol. Atherosclerosis. 1998; 137 (1): 215-221.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000103&pid=S0124-0064201000040001000024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  25. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. The Am J   Card 2001; 88(12A): 3N-8N.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000104&pid=S0124-0064201000040001000025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  26. Coqueiro RS, Pelegrini A, Corseuil MW, Nery AA, Cruz ZV, S&aacute; CKC. Fatores associados &agrave;   hipertens&atilde;o arterial em adultos acompanhados por uma unidade de sa&uacute;de da fam&iacute;lia.   Rev Bras Med 2009; 66(2): 17-23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000105&pid=S0124-0064201000040001000026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  27. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration.   Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis   of usual blood pressure to vascular mortality: a meta-analysis of individual data for   one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-1913.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000106&pid=S0124-0064201000040001000027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  28. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA, et al. American   College of Sports Medicine position stand: Exercise and Hypertension. Med Sci Sports   Exerc 2004; 36(3): 533-553.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000107&pid=S0124-0064201000040001000028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  29. Gidding SS. The aging of the cardiovascular system: when should children be treated like   adults? J Pediatr 2002; 141(2): 159-161.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000108&pid=S0124-0064201000040001000029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  30. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults:   Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002;   287(3): 356-359.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000109&pid=S0124-0064201000040001000030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>  31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults:   findings from the third National Health and Nutrition Examination Survey. JAMA 2002;   287 (3): 356-359.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000110&pid=S0124-0064201000040001000031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pozzan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pozzan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Magalhães]]></surname>
<given-names><![CDATA[MEC]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Dislipidemia, síndrome metabólica e risco cardiovascular]]></article-title>
<source><![CDATA[RSOCERJ]]></source>
<year>2004</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-104</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Anjos]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Aspectos das práticas alimentares e da atividade física como determinantes do crescimento do sobrepeso/obesidade no Brasil]]></article-title>
<source><![CDATA[Cad Saúde Pública]]></source>
<year>2004</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>698-709</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lakka]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Laaksonen]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Lakka]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Niskanem]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Kumpusalo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tuomilehto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>288</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2709-2716</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azambuja]]></surname>
<given-names><![CDATA[MIR]]></given-names>
</name>
<name>
<surname><![CDATA[Foppa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Maranhao]]></surname>
<given-names><![CDATA[MFC]]></given-names>
</name>
<name>
<surname><![CDATA[Achutti]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Impacto econômico dos casos de doença cardiovascular grave no Brasil: uma estimativa baseada em dados secundários]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2008</year>
<volume>91</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>163-171</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Nogueira]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Suplicy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brandão]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2005</year>
<volume>84</volume>
<numero>^sI</numero>
<issue>^sI</issue>
<supplement>I</supplement>
<page-range>1-28</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>Sociedade Brasileira de Hipertensão</collab>
<article-title xml:lang="pt"><![CDATA[I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica]]></article-title>
<source><![CDATA[Hipertensão]]></source>
<year>2004</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salaroli]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Mill]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[MCB]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Prevalência de Síndrome Metabólica em Estudo de Base Populacional, Vitória, ES - Brasil]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metab]]></source>
<year>2007</year>
<volume>51</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1143- 1152</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velásquez-Meléndez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gazzinelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Côrrea-Oliveira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pimenta]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kac]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of metabolic syndrome in a rural area of Brazil]]></article-title>
<source><![CDATA[Sao Paulo Med J]]></source>
<year>2007</year>
<volume>125</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>155-162</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Giles]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A comparison of the prevalence of the metabolic syndrome using two proposed definitions]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2003</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>575-581</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Qiao]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Tuomilehto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Balkau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Borch-Johnsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pyorala]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men in women]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2004</year>
<volume>164</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1066-1076</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguilar-Salinas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Perez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Valles]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rios-Torres]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High prevalence of metabolic syndrome in Mexico]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2004</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[Y-A]]></given-names>
</name>
<name>
<surname><![CDATA[Connor-Barrett]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and factor analysis of metabolic syndrome in an urban Korean population]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2027-2032</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Pavan]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Alturas e comprimentos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Petroski]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<source><![CDATA[Antropometria: técnicas e padronizações]]></source>
<year>2003</year>
<edition>2</edition>
<page-range>59-71</page-range><publisher-loc><![CDATA[Porto Alegre ]]></publisher-loc>
<publisher-name><![CDATA[EL Petroski]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Athyros]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Ganotakis]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Bathianaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Monedas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Goudevenos]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Papageorgiou]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2005</year>
<volume>46</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>380-386</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palaniappan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heshka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carnethon]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Heymsfield]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2003</year>
<volume>163</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-436</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Lawati]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammed]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Hinai]]></surname>
<given-names><![CDATA[HQ]]></given-names>
</name>
<name>
<surname><![CDATA[Jousilahti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of the metabolic syndrome among Omani adults]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2003</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1781-1785</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The metabolic syndrome and associated lifestyle factors among South Korean adults]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>2004</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>328-336</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polanczyk]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fatores de risco cardiovascular no Brasil: os próximos 50 anos]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2005</year>
<volume>84</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-201</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vedana]]></surname>
<given-names><![CDATA[EHB]]></given-names>
</name>
<name>
<surname><![CDATA[Peres]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[GZ]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Prevalência de obesidade e fatores potencialmente causais em adultos em região do sul do Brasil]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metab]]></source>
<year>2008</year>
<volume>52</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1156-62</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erem]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hacihasanoglu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Deger]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kocak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Topbas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study]]></article-title>
<source><![CDATA[Endocrine]]></source>
<year>2008</year>
<volume>34</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>36-51</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morimoto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Matsudaira]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Taki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tsujino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Low prevalence of metabolic syndrome and its components in rural Japan]]></article-title>
<source><![CDATA[Tohoku J Exp Med]]></source>
<year>2008</year>
<volume>216</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-75</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sodjinou]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Agueh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fayomi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Delisle]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Obesity and cardio-metabolic risk factors in urban adults of Benin: relationship with socio-economic status, urbanisation, and lifestyle patterns]]></article-title>
<source><![CDATA[BMC Public Health]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>84</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Buring]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2007</year>
<volume>116</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2110-2118</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zmuda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yurgalevich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>1998</year>
<volume>137</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>215-221</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Managing the risk of atherosclerosis: the role of high-density lipoprotein]]></article-title>
<source><![CDATA[The Am J Card]]></source>
<year>2001</year>
<volume>88</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3N-8N</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coqueiro]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Pelegrini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corseuil]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Nery]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[ZV]]></given-names>
</name>
<name>
<surname><![CDATA[Sá]]></surname>
<given-names><![CDATA[CKC]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Fatores associados Ã  hipertensão arterial em adultos acompanhados por uma unidade de saúde da família]]></article-title>
<source><![CDATA[Rev Bras Med]]></source>
<year>2009</year>
<volume>66</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>17-23</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewington]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Qizilbash]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<numero>9349</numero>
<issue>9349</issue>
<page-range>1903-1913</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pescatello]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Farquhar]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Kelley]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[American College of Sports Medicine position stand: Exercise and Hypertension]]></article-title>
<source><![CDATA[Med Sci Sports Exerc]]></source>
<year>2004</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>533-553</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gidding]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The aging of the cardiovascular system: when should children be treated like adults?]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2002</year>
<volume>141</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>159-161</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Giles]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Dietz]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>287</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>356-359</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Giles]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Dietz]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>287</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>356-359</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
